Key result
Iloprost shows promising potential in combination therapy as an approved prostacyclin analog for idiopathic PAH.
Why the study?
Idiopathic pulmonary arterial hypertension is a rare, life-threatening disease with limited treatment options, necessitating evaluation of iloprost's efficacy and safety.
What is the role, efficacy, and safety of iloprost in patients with idiopathic pulmonary arterial hypertension?
What is the role, efficacy, and safety of iloprost in patients with idiopathic pulmonary arterial hypertension?
This review outlines the pharmacology, efficacy, and safety of iloprost for idiopathic pulmonary arterial hypertension, highlighting its potential role in future combination therapies.
Affirms iloprost's approved role in IPAH; leaves open combination efficacy for randomized trials.
Idiopathic pulmonary arterial hypertension is a rare but serious and life-threatening disease that leads to right heart failure and death within 2.8 years without specific treatment. This review focuses on the stable prostacyclin analog iloprost, its biologic action and pharmacology and, finally, on its clinical development, efficacy and safety in patients with idiopathic pulmonary arterial hypertension, which led to its approval for this indication. Furthermore, this review assesses the role of iloprost compared with other newly developed drugs, such as the endothelin receptor antagonist bosentan and the phosphodiesterase-5 inhibitor sildenafil, as well as other modes of application of prostacyclin and its analogs for the treatment of idiopathic pulmonary arterial hypertension. Based on the different modes of action of these substances, a combination of these treatments could be most promising for the future.
No takes yet. Share an insight, caveat, or question.
Leuchte et al. (2005) conducted a review in Idiopathic pulmonary arterial hypertension. Iloprost vs. Bosentan, sildenafil, and other prostacyclin analogs was evaluated. Iloprost is an approved stable prostacyclin analog for idiopathic pulmonary arterial hypertension, and combination therapy with other agents may be promising for the future.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Expert Review of Cardiovascular Therapy